Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive candidiasis in children supported with extracorporeal membrane oxygenation

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3935-3943

  Watt, Kevin M ^a,b   Gonzalez, Daniel ^a,b   Benjamin, Daniel K ^a   Brouwer, Kim L R ^b   Wade, Kelly C ^c   Capparelli, Edmund ^d   Barrett, Jeffrey ^c   Cohen Wolkowiez, Michael ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FLUCONAZOLE; ANTIFUNGAL AGENT;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; DRUG CLEARANCE; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; INFANT; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; NEWBORN; PRIORITY JOURNAL; PROPHYLAXIS; VOLUME OF DISTRIBUTION; ADOLESCENT; BLOOD; CANDIDIASIS, INVASIVE; CLINICAL TRIAL; CRITICAL ILLNESS; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; POPULATION; PRESCHOOL CHILD; STATISTICAL MODEL;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ANTIFUNGAL AGENTS; BODY WEIGHT; CANDIDIASIS, INVASIVE; CHILD; CHILD, PRESCHOOL; CREATININE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; FLUCONAZOLE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MODELS, STATISTICAL; POPULATION;

EID: 84935911865     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00102-15     Document Type: Article

References (29)

1. ELSO. 2013. ECLS registry report: international summary. Extracorporeal Life Support Organization, Ann Arbor, MI.
2. Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P, Extracorporeal Life Support Organization Task Force on Infections, Extracorporeal Membrane Oxygenation. 2010. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med 12:277-281. http://dx.doi.org/10.1097/PCC.0b013e3181e28894.
3. Gardner AH, Prodhan P, Stovall SH, Gossett JM, Stern JE, Wilson CD, Fiser RT. 2011. Fungal infections and antifungal prophylaxis in pediatric cardiac extracorporeal life support. J Thorac Cardiovasc Surg 143:689-695. http://dx.doi.org/10.1016/j.jtcvs.2011.12.001.
4. Eppes SC, Troutman JL, Gutman LT. 1989. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 8:99-104.
5. Bhatt-Mehta V, Johnson CE, Schumacher RE. 1992. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 12:28-32.
6. Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR. 2003. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology 99:275-282. http://dx.doi.org/10 .1097/00000542-200308000-00008.
7. Veinstein A, Debouverie O, Gregoire N, Goudet V, Adier C, Robert R, Couet W. 2011. Lack of effect of extracorporeal membrane oxygenation on tigecycline pharmacokinetics. J Antimicrob Chemother 67:1047-1048. http://dx.doi.org/10.1093/jac/dkr550.
8. Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D. 2010. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 36:2109-2116. http://dx.doi.org/10.1007/s00134-010-2041-z.
9. Watt KM, Benjamin DK, Jr, Cheifetz IM, Moorthy G, Wade KC, Smith PB, Brouwer KL, Capparelli EV, Cohen-Wolkowiez M. 2012. Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J 31:1042-1047. http://dx.doi.org/10.1097/INF.0b013e31285d3091.
10. Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, Hope WW, Wade KC, Cohen-Wolkowiez M, Benjamin DK, Jr. 2011. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 30: 375-378. http://dx.doi.org/10.1097/INF.0b013e318202cbb3.
11. Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK, Jr, Sullivan JE, Ramey N, Jayaraman B, Hoppu K, Adamson PC, Gastonguay MR, Barrett JS, NICHD Pediatric Pharmacology Research Unit Network. 2008. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 52:4043-4049. http://dx.doi.org/10.1128 /AAC.00569-08.
12. Wu D, Wade KC, Paul DJ, Barrett JS. 2009. A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. Ther Drug Monit 31:703-709. http://dx.doi.org/10.1097/FTD.0b013e3181b20b40.
13. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257. http://dx.doi.org/10.1016/j.cmpb.2005.04.005.
14. Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. 2011. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 101:72-79. http://dx .doi.org/10.1016/j.cmpb.2010.04.018.
15. Andes D, van Ogtrop M. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43:2116-2120.
16. Clancy CJ, Staley B, Nguyen MH. 2006. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother 50:3496-3498. http://dx.doi.org/10.1128/AAC.00741-06.
17. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 49: 3171-3177. http://dx.doi.org/10.1128/AAC.49.8.3171-3177.2005.
18. Pai MP, Turpin RS, Garey KW. 2007. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 51:35-39. http://dx.doi.org/10.1128/AAC.00474-06.
19. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Disease Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org/10.1086/596757.
20. Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N, Keirns J, Lau W, Facklam D, Buell D. 2005. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 49:1331-1336. http://dx.doi.org/10.1128/AAC.49.4.1331-1336.2005.
21. Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA. 2001. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med 27:115-121. http://dx.doi.org/10.1007/s001340000771.
22. Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L. 2006. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 50:2374-2383. http://dx.doi.org/10.1128/AAC.01053-05.
23. Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA, Bosso J, Bodey GP. 1995. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 172:599-602. http://dx.doi.org/10.1093/infdis/172.2.599.
24. Brammer KW, Coates PE. 1994. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 13:325-329. http://dx .doi.org/10.1007/BF01974613.
25. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. 1993. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 15:263-266. http://dx.doi.org/10.1097/00007691-199308000-00001.
26. Muhl E, Martens T, Iven H, Rob P, Bruch HP. 2000. Influence of continuous veno-venous haemodiafiltration and continuous venovenous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 56:671-678. http://dx.doi.org/10.1007/s002280000216.
27. Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hirano T, Iseki K. 2003. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 29:1844-1848. http://dx.doi.org/10.1007/s00134-003 -1980-z.
28. Valtonen M, Tiula E, Neuvonen PJ. 1997. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 40:695-700. http://dx.doi.org/10.1093/jac/40.5.695.
29. Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM. 2011. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 55:5868-5873. http://dx.doi.org/10.1128 /AAC.00424-11.